Medgenics, Inc. (MDGN)
-NYSE MKT 4.15 
0.03(0.72%) 4:00PM EDT
| Prev Close: | 4.18 |
|---|
| Open: | 4.23 |
|---|
| Bid: | 3.77 x 200 |
|---|
| Ask: | 4.17 x 100 |
|---|
| 1y Target Est: | 13.50 |
|---|
| Beta: | 1.02 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.08 - 4.23 |
|---|
| 52wk Range: | 3.66 - 16.43 |
|---|
| Volume: | 4,530 |
|---|
| Avg Vol (3m): | 46,924 |
|---|
| Market Cap: | 76.70M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MEDGENICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Medgenics Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu, May 9)
- MEDGENICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- MEDGENICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecEDGAR Online(Wed, May 1)
- Medgenics Announces Results of 2013 Annual Meeting of StockholdersBusiness Wire(Wed, May 1)
- Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis PatientsBusiness Wire(Thu, Apr 25)
- Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic ProteinsBusiness Wire(Mon, Apr 22)
- Medgenics to Present at the 12th Annual Needham Healthcare ConferenceBusiness Wire(Thu, Apr 18)
- MEDGENICS, INC. Files SEC form 8-K/A, Change in Directors or Principal OfficersEDGAR Online(Wed, Apr 17)
- MEDGENICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Mar 26)
- Medgenics Announces Exercise by Underwriters of Over-Allotment OptionBusiness Wire(Tue, Mar 26)
- New Star Analyst Rankings for MEDGENICS, INC.StarMine(Sat, Mar 16)
- Medgenics to Present at the 25th Annual Roth ConferenceBusiness Wire(Fri, Mar 15)
- MEDGENICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial StEDGAR Online(Thu, Mar 14)
- Medgenics Reports 2012 Financial ResultsBusiness Wire(Thu, Mar 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.07 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.26 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Medgenics, Inc., a medical technology and therapeutics company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States.
View More